What is the P/E ratio of LigaChem Biosciences 2024?
The LigaChem Biosciences P/E ratio is -111.18.
Own the gold standard ✨ in financial data & analytics fair value · 20 million securities worldwide · 50 year history · 10 year estimates · leading business news
Subscribe for $2 fair value · 20 million securities worldwide · 50 year history · 10 year estimates · leading business news
Overview
Profile
LigaChem Biosciences stock price, quote, forecast and news stock price, forecast, news, chart, split, dividend and analysis LigaChem Biosciences ariva, LigaChem Biosciences onvista, LigaChem Biosciences finanzen.net, LigaChem Biosciences aktienfinder, LigaChem Biosciences marketscreener, LigaChem Biosciences marketwatch, LigaChem Biosciences bloomberg, LigaChem Biosciences handelsblatt, LigaChem Biosciences wiwo, LigaChem Biosciences forum
141080.KQ
KR7141080002
Price
Price
89,200.00
Today +/-
+0.95
Today %
+1.58 %
Ticker141080.KQ
ISINKR7141080002
P
LigaChem Biosciences stock price
%
Weekly
Details
Price
ⓘOverview
The Quote Chart provides detailed and dynamic insights into the LigaChem Biosciences stock's performance, showcasing daily, weekly, or monthly aggregated quotes. Users can switch between different time frames to analyze the stock's progression meticulously and make informed investment decisions.
Intraday Feature
The intraday feature provides real-time data, allowing investors to view the LigaChem Biosciences stock’s price fluctuations within the trading day, facilitating timely and strategic investment decisions.
Total Return and Relative Price Change
View the total return of the LigaChem Biosciences stock to gauge its profitability over time. The relative price change, based on the first quote available in the selected timeframe, offers insights into the stock’s performance, assisting in evaluating its investment potential.
Interpretation and Investment
Utilize the comprehensive data presented in the Quote Chart to analyze LigaChem Biosciences's market trends, price movements, and potential returns. Make informed investment choices by comparing different time frames and evaluating intraday data for optimized portfolio management.
LigaChem Biosciences Stock Price History
| Date | LigaChem Biosciences Price |
|---|---|
| 9/13/2024 | 89,200.00 undefined |
| 9/12/2024 | 87,800.00 undefined |
| 9/11/2024 | 83,900.00 undefined |
| 9/10/2024 | 86,300.00 undefined |
| 9/9/2024 | 87,400.00 undefined |
| 9/6/2024 | 83,200.00 undefined |
| 9/5/2024 | 84,000.00 undefined |
| 9/4/2024 | 86,600.00 undefined |
| 9/3/2024 | 91,200.00 undefined |
| 9/2/2024 | 95,000.00 undefined |
| 8/30/2024 | 96,600.00 undefined |
| 8/29/2024 | 94,800.00 undefined |
| 8/28/2024 | 95,200.00 undefined |
| 8/27/2024 | 95,600.00 undefined |
| 8/26/2024 | 98,000.00 undefined |
| 8/23/2024 | 93,700.00 undefined |
| 8/22/2024 | 89,300.00 undefined |
| 8/21/2024 | 91,300.00 undefined |
| 8/20/2024 | 92,700.00 undefined |
| 8/19/2024 | 93,800.00 undefined |
LigaChem Biosciences Revenue, EBIT, Net Income KR7141080002 ·
3 years
5 years
10 years
25 Years
Max
Revenue
EBIT
Net Income
Details
Revenue, EBIT and Profit
ⓘUnderstanding Revenue, EBIT, and Income
Gain insights into LigaChem Biosciences, a comprehensive overview of its financial performance can be obtained by analyzing the Revenue, EBIT, and Income chart. Revenue represents the total income generated by LigaChem Biosciences from its primary operations, showcasing the company’s ability to attract and retain clients. EBIT, or Earnings Before Interest and Taxes, indicates the company’s operational profitability, free from the influence of tax and interest expenses. The Income section reflects LigaChem Biosciences’s net earnings, an ultimate measure of its financial health and profitability.
Yearly Analysis and Comparisons
Observe the yearly bars to understand the annual performance and growth of LigaChem Biosciences. Compare the Revenue, EBIT, and Income to evaluate the company’s efficiency and profitability. A higher EBIT compared to the previous year suggests an improvement in operational efficiency. Likewise, an increase in Income indicates enhanced overall profitability. Analyzing the year-to-year comparison assists investors in understanding the company’s growth trajectory and operational efficiency.
Utilizing Expectations for Investment
The expected values for the forthcoming years offer investors a glimpse into LigaChem Biosciences’s anticipated financial performance. Analyzing these projections alongside historical data aids in making informed investment decisions. Investors can gauge the potential risks and returns, aligning their investment strategies accordingly to optimize profitability and mitigate risks.
Investment Insights
Leveraging the comparison between Revenue and EBIT helps in assessing LigaChem Biosciences’s operational efficiency, while the Revenue and Income comparison reveals the net profitability after accounting for all expenses. Investors can derive valuable insights by meticulously analyzing these financial parameters, laying the foundation for strategic investment decisions aimed at capitalizing on LigaChem Biosciences’s growth potential.
LigaChem Biosciences Revenue, EBIT and net profit per share
| Date | LigaChem Biosciences Revenue | LigaChem Biosciences EBIT | LigaChem Biosciences Net Income |
|---|---|---|---|
| 2026e | 205 B undefined | 20.6 B undefined | 24.67 B undefined |
| 2025e | 233.06 B undefined | 77.71 B undefined | 66.56 B undefined |
| 2024e | 105.36 B undefined | -27.46 B undefined | -22.79 B undefined |
| 2023 | 34.15 B undefined | -80.82 B undefined | -73.7 B undefined |
| 2022 | 33.41 B undefined | -50.38 B undefined | -45.09 B undefined |
| 2021 | 32.16 B undefined | -27.71 B undefined | -23.39 B undefined |
| 2020 | 49.39 B undefined | -29.76 B undefined | -6.99 B undefined |
| 2019 | 57.5 B undefined | 8.42 B undefined | 13.59 B undefined |
| 2018 | 25.24 B undefined | -15.98 B undefined | -25.77 B undefined |
| 2017 | 22.06 B undefined | -9.84 B undefined | -12.93 B undefined |
| 2016 | 16.66 B undefined | -10.17 B undefined | -14.73 B undefined |
| 2015 | 1.79 B undefined | -8.05 B undefined | -8.24 B undefined |
| 2014 | 870 M undefined | -8.46 B undefined | -8.69 B undefined |
| 2013 | 840 M undefined | -6.26 B undefined | -5.84 B undefined |
| 2012 | 744 M undefined | -3.25 B undefined | -2.67 B undefined |
| 2011 | 79 M undefined | -3.06 B undefined | -3.07 B undefined |
| 2010 | 270 M undefined | -3.07 B undefined | -3.34 B undefined |
| 2009 | 1.7 B undefined | -429 M undefined | -466 M undefined |
| 2008 | 338 M undefined | -1.27 B undefined | -1.27 B undefined |
| Revenue | EBIT | Net Income | |
|---|---|---|---|
| 2008 | 338 M KRW | -1.27 B KRW | -1.27 B KRW |
| 2009 | 1.7 B KRW | -429 M KRW | -466 M KRW |
| 2010 | 270 M KRW | -3.07 B KRW | -3.34 B KRW |
| 2011 | 79 M KRW | -3.06 B KRW | -3.07 B KRW |
| 2012 | 744 M KRW | -3.25 B KRW | -2.67 B KRW |
| 2013 | 840 M KRW | -6.26 B KRW | -5.84 B KRW |
| 2014 | 870 M KRW | -8.46 B KRW | -8.69 B KRW |
| 2015 | 1.79 B KRW | -8.05 B KRW | -8.24 B KRW |
| 2016 | 16.66 B KRW | -10.17 B KRW | -14.73 B KRW |
| 2017 | 22.06 B KRW | -9.84 B KRW | -12.93 B KRW |
| 2018 | 25.24 B KRW | -15.98 B KRW | -25.77 B KRW |
| 2019 | 57.5 B KRW | 8.42 B KRW | 13.59 B KRW |
| 2020 | 49.39 B KRW | -29.76 B KRW | -6.99 B KRW |
| 2021 | 32.16 B KRW | -27.71 B KRW | -23.39 B KRW |
| 2022 | 33.41 B KRW | -50.38 B KRW | -45.09 B KRW |
| 2023 | 34.15 B KRW | -80.82 B KRW | -73.7 B KRW |
| 2024e | 105.36 B KRW | -27.46 B KRW | -22.79 B KRW |
| 2025e | 233.06 B KRW | 77.71 B KRW | 66.56 B KRW |
| 2026e | 205 B KRW | 20.6 B KRW | 24.67 B KRW |
LigaChem Biosciences Income Statement, Balance Sheet, Cash Flow Statement
Simple
Expanded
Income Statement
Balance Sheet
Cashflow
| 2008 | 2009 | 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024e | 2025e | 2026e |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 0.34 | 1.7 | 0.27 | 0.08 | 0.74 | 0.84 | 0.87 | 1.79 | 16.66 | 22.06 | 25.24 | 57.5 | 49.39 | 32.16 | 33.41 | 34.15 | 105.36 | 233.06 | 205 |
| - | 402.37 | -84.10 | -70.74 | 841.77 | 12.90 | 3.57 | 105.52 | 831.49 | 32.43 | 14.43 | 127.81 | -14.10 | -34.90 | 3.90 | 2.19 | 208.56 | 121.21 | -12.04 |
| 39.94 | 41.52 | 3.33 | 67.09 | 68.01 | - | - | 61.41 | 25.17 | 30.47 | 23.41 | 60.54 | 72.00 | 55.03 | 53.42 | 52.12 | - | - | - |
| 0.14 | 0.71 | 0.01 | 0.05 | 0.51 | 0 | 0 | 1.1 | 4.19 | 6.72 | 5.91 | 34.81 | 35.57 | 17.7 | 17.85 | 17.8 | 0 | 0 | 0 |
| -1.27 | -0.43 | -3.07 | -3.06 | -3.25 | -6.26 | -8.46 | -8.05 | -10.17 | -9.84 | -15.98 | 8.42 | -29.76 | -27.71 | -50.38 | -80.82 | -27.46 | 77.71 | 20.6 |
| -376.33 | -25.27 | -1,135.56 | -3,875.95 | -437.10 | -745.24 | -972.07 | -450.17 | -61.08 | -44.62 | -63.30 | 14.64 | -60.25 | -86.16 | -150.77 | -236.70 | -26.07 | 33.34 | 10.05 |
| -1.27 | -0.47 | -3.34 | -3.07 | -2.67 | -5.84 | -8.69 | -8.24 | -14.73 | -12.93 | -25.77 | 13.59 | -6.99 | -23.39 | -45.09 | -73.7 | -22.79 | 66.56 | 24.67 |
| - | -63.34 | 616.09 | -8.00 | -12.90 | 118.21 | 48.86 | -5.17 | 78.77 | -12.16 | 99.24 | -152.72 | -151.42 | 234.83 | 92.77 | 63.45 | -69.08 | -392.10 | -62.93 |
| 7 | 8 | 9 | 9 | 11 | 13 | 14 | 15 | 19 | 20 | 21 | 24 | 23 | 24.12 | 24.36 | 28.4 | 0 | 0 | 0 |
| - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Details
Keystats
ⓘRevenue and Growth
The LigaChem Biosciences Revenue and Revenue Growth are pivotal to understanding the company's financial health and operational efficiency. A consistent increase in revenue indicates a company’s ability to effectively market and sell its products or services, while the revenue growth percentage offers insights into the pace at which the company is expanding over the years.
Gross Margin
The Gross Margin is a crucial metric that showcases the percentage of revenue exceeding the cost of goods sold (COGS). A higher gross margin is indicative of a company’s efficiency in controlling its production costs, thereby promising potential profitability and financial stability.
EBIT and EBIT Margin
EBIT (Earnings Before Interest and Taxes) and EBIT Margin offer deep insights into a company’s profitability, excluding the impacts of interest and taxes. Investors often assess these metrics to gauge the operational efficiency and inherent profitability of a business, separate from its financial structure and tax environment.
Income and Growth
Net Income and its subsequent growth are quintessential for investors looking to understand a company’s profitability. Consistent income growth underscores a company’s ability to enhance its profitability over time, reflecting operational efficiency, strategic competitiveness, and financial health.
Shares Outstanding
Shares outstanding refer to the total number of shares a company has issued. It's instrumental in calculating key metrics like Earnings Per Share (EPS) which is pivotal for investors to evaluate a company’s profitability on a per-share basis, offering a more granular view of financial health and valuation.
Interpreting Year to Year Comparison
Comparing yearly data allows investors to identify trends, assess the company’s growth, and anticipate potential future performance. Analyzing how metrics like revenue, income, and margins change year over year can provide valuable insights into the company’s operational efficiency, competitiveness, and overall financial health.
Expectations and Predictions
Investors often juxtapose the current and past financial data with the market’s expectations. This comparison aids in assessing whether the LigaChem Biosciences is performing as anticipated, underperforming or outperforming the market predictions, providing pivotal data for investment decisions.
LigaChem Biosciences stock margins KR7141080002 ·
The LigaChem Biosciences margin analysis displays the gross margin, EBIT margin, as well as the profit margin of LigaChem Biosciences. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for LigaChem Biosciences.
3 years
5 years
10 years
25 Years
Max
Gross margin
EBIT margin
Profit margin
Details
Margin
ⓘUnderstanding Gross Margin
The gross margin, expressed as a percentage, delineates the gross profit made from the LigaChem Biosciences's sales revenue. A higher gross margin percentage indicates that the LigaChem Biosciences retains more revenue after accounting for the costs of goods sold. Investors use this metric to gauge financial health and operational efficiency, as well as to compare it with competitors and industry averages.
EBIT Margin Analysis
EBIT margin represents the LigaChem Biosciences's earnings before interest and taxes. Analyzing the EBIT margin over different years provides insights into the operational profitability and efficiency, excluding the effects of financial leverage and tax structure. A growing EBIT margin over the years signifies improving operational performance.
Revenue Margin Insights
The revenue margin demonstrates the LigaChem Biosciences's total revenue generated. When comparing the revenue margin year over year, investors can gauge the LigaChem Biosciences's growth and market expansion. It is essential to compare the revenue margin with the gross and EBIT margins to understand the cost and profit structures better.
Interpreting Expectations
The expected values for gross, EBIT, and revenue margins provide future financial outlook of the LigaChem Biosciences. Investors should compare these expectations with historical data to understand potential growth and risk factors. It is crucial to consider the underlying assumptions and methodologies used in projecting these expected values to make informed investment decisions.
Comparative Analysis
Comparing the gross, EBIT, and revenue margins, both yearly and over multiple years, enables investors to perform a comprehensive analysis of the LigaChem Biosciences's financial health and growth prospects. Evaluating the trends and patterns in these margins helps in identifying strengths, weaknesses, and potential investment opportunities.
LigaChem Biosciences Margin History
| LigaChem Biosciences Gross margin | LigaChem Biosciences Profit margin | LigaChem Biosciences EBIT margin | LigaChem Biosciences Profit margin |
|---|---|---|---|
| 2026e | 52.12 % | 10.05 % | 12.04 % |
| 2025e | 52.12 % | 33.34 % | 28.56 % |
| 2024e | 52.12 % | -26.07 % | -21.63 % |
| 2023 | 52.12 % | -236.7 % | -215.85 % |
| 2022 | 53.42 % | -150.77 % | -134.96 % |
| 2021 | 55.03 % | -86.16 % | -72.74 % |
| 2020 | 72 % | -60.25 % | -14.14 % |
| 2019 | 60.54 % | 14.64 % | 23.63 % |
| 2018 | 23.41 % | -63.3 % | -102.1 % |
| 2017 | 30.47 % | -44.62 % | -58.64 % |
| 2016 | 25.17 % | -61.08 % | -88.41 % |
| 2015 | 61.41 % | -450.17 % | -460.68 % |
| 2014 | 52.12 % | -972.07 % | -998.39 % |
| 2013 | 52.12 % | -745.24 % | -694.64 % |
| 2012 | 68.01 % | -437.1 % | -359.41 % |
| 2011 | 67.09 % | -3,875.95 % | -3,886.08 % |
| 2010 | 3.33 % | -1,135.56 % | -1,235.93 % |
| 2009 | 41.52 % | -25.27 % | -27.44 % |
| 2008 | 39.94 % | -376.33 % | -376.04 % |
| Gross margin | EBIT margin | Profit margin | |
|---|---|---|---|
| 2008 | 39.94 % | -376.33 % | -376.04 % |
| 2009 | 41.52 % | -25.27 % | -27.44 % |
| 2010 | 3.33 % | -1,135.56 % | -1,235.93 % |
| 2011 | 67.09 % | -3,875.95 % | -3,886.08 % |
| 2012 | 68.01 % | -437.1 % | -359.41 % |
| 2013 | 52.12 % | -745.24 % | -694.64 % |
| 2014 | 52.12 % | -972.07 % | -998.39 % |
| 2015 | 61.41 % | -450.17 % | -460.68 % |
| 2016 | 25.17 % | -61.08 % | -88.41 % |
| 2017 | 30.47 % | -44.62 % | -58.64 % |
| 2018 | 23.41 % | -63.3 % | -102.1 % |
| 2019 | 60.54 % | 14.64 % | 23.63 % |
| 2020 | 72 % | -60.25 % | -14.14 % |
| 2021 | 55.03 % | -86.16 % | -72.74 % |
| 2022 | 53.42 % | -150.77 % | -134.96 % |
| 2023 | 52.12 % | -236.7 % | -215.85 % |
| 2024e | 52.12 % | -26.07 % | -21.63 % |
| 2025e | 52.12 % | 33.34 % | 28.56 % |
| 2026e | 52.12 % | 10.05 % | 12.04 % |
LigaChem Biosciences Stock Sales Revenue, EBIT, Earnings per Share KR7141080002 ·
The LigaChem Biosciences earnings per share therefore indicates how much revenue LigaChem Biosciences has generated per share in a given period. The earnings before interest and taxes per share shows how much of the operating profit corresponds to each share. The earnings per share indicates how much of the profit belongs to each share.
3 years
5 years
10 years
25 Years
Max
Sales per Share
EBIT per share
Earnings per Share
Details
Revenue, EBIT and Earnings per share
ⓘRevenue Per Share
Revenue per share represents the total revenue LigaChem Biosciences earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.
EBIT Per Share
EBIT per share indicates LigaChem Biosciences's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.
Income Per Share
Income per share, or earnings per share (EPS), reveals the portion of LigaChem Biosciences’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.
Expected Values
Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating LigaChem Biosciences's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.
LigaChem Biosciences Revenue, EBIT and net profit per share
| Date | LigaChem Biosciences Sales per Share | LigaChem Biosciences EBIT per share | LigaChem Biosciences Earnings per Share |
|---|---|---|---|
| 2026e | 5,627.54 undefined | 0 undefined | 677.37 undefined |
| 2025e | 6,398.06 undefined | 0 undefined | 1,827.25 undefined |
| 2024e | 2,892.25 undefined | 0 undefined | -625.57 undefined |
| 2023 | 1,202.14 undefined | -2,845.45 undefined | -2,594.83 undefined |
| 2022 | 1,371.43 undefined | -2,067.7 undefined | -1,850.84 undefined |
| 2021 | 1,332.94 undefined | -1,148.47 undefined | -969.59 undefined |
| 2020 | 2,147.57 undefined | -1,294 undefined | -303.74 undefined |
| 2019 | 2,395.83 undefined | 350.71 undefined | 566.08 undefined |
| 2018 | 1,201.9 undefined | -760.86 undefined | -1,227.14 undefined |
| 2017 | 1,102.85 undefined | -492.1 undefined | -646.7 undefined |
| 2016 | 876.58 undefined | -535.42 undefined | -775 undefined |
| 2015 | 119.2 undefined | -536.6 undefined | -549.13 undefined |
| 2014 | 62.14 undefined | -604.07 undefined | -620.43 undefined |
| 2013 | 64.62 undefined | -481.54 undefined | -448.85 undefined |
| 2012 | 67.64 undefined | -295.64 undefined | -243.09 undefined |
| 2011 | 8.78 undefined | -340.22 undefined | -341.11 undefined |
| 2010 | 30 undefined | -340.67 undefined | -370.78 undefined |
| 2009 | 212.25 undefined | -53.63 undefined | -58.25 undefined |
| 2008 | 48.29 undefined | -181.71 undefined | -181.57 undefined |
| Sales per Share | EBIT per share | Earnings per Share | |
|---|---|---|---|
| 2008 | 48.29 KRW | -181.71 KRW | -181.57 KRW |
| 2009 | 212.25 KRW | -53.63 KRW | -58.25 KRW |
| 2010 | 30 KRW | -340.67 KRW | -370.78 KRW |
| 2011 | 8.78 KRW | -340.22 KRW | -341.11 KRW |
| 2012 | 67.64 KRW | -295.64 KRW | -243.09 KRW |
| 2013 | 64.62 KRW | -481.54 KRW | -448.85 KRW |
| 2014 | 62.14 KRW | -604.07 KRW | -620.43 KRW |
| 2015 | 119.2 KRW | -536.6 KRW | -549.13 KRW |
| 2016 | 876.58 KRW | -535.42 KRW | -775 KRW |
| 2017 | 1,102.85 KRW | -492.1 KRW | -646.7 KRW |
| 2018 | 1,201.9 KRW | -760.86 KRW | -1,227.14 KRW |
| 2019 | 2,395.83 KRW | 350.71 KRW | 566.08 KRW |
| 2020 | 2,147.57 KRW | -1,294 KRW | -303.74 KRW |
| 2021 | 1,332.94 KRW | -1,148.47 KRW | -969.59 KRW |
| 2022 | 1,371.43 KRW | -2,067.7 KRW | -1,850.84 KRW |
| 2023 | 1,202.14 KRW | -2,845.45 KRW | -2,594.83 KRW |
| 2024e | 2,892.25 KRW | 0 KRW | -625.57 KRW |
| 2025e | 6,398.06 KRW | 0 KRW | 1,827.25 KRW |
| 2026e | 5,627.54 KRW | 0 KRW | 677.37 KRW |
LigaChem Biosciences business model
LigaChem Biosciences is one of the most popular companies on Eulerpool.com.
LigaChem Biosciences Eulerpool Fair Value
Details
Fair Value
ⓘUnderstanding Fair Value
The fair value of a stock provides insights into whether the stock is currently undervalued or overvalued. It is calculated based on profit, revenue, or dividends and offers a comprehensive perspective of the stock’s intrinsic value.
Income-Based Fair Value
This is calculated by multiplying the earnings per share by the average P/E ratio of the selected past years for smoothing. If the fair value is higher than the current market price, it suggests that the stock is undervalued.
Example 2022
Fair Value Profit 2022 = Earnings per Share 2022 / Average P/E Ratio 2019 - 2021 (3 Years Smoothing)
Revenue-Based Fair Value
It is derived by multiplying the revenue per share by the average price-to-sales ratio of the selected past years for smoothing. An undervalued stock is identified if the fair value exceeds the ongoing market price.
Example 2022
Fair Value Revenue 2022 = Revenue per Share 2022 / Average PSR 2019 - 2021 (3 Years Smoothing)
Dividend-Based Fair Value
This value is determined by dividing the dividend per share by the average dividend yield of the selected past years for smoothing. A higher fair value than the market price indicates an undervalued stock.
Example 2022
Fair Value Dividend 2022 = Dividend per Share 2022 * Average Dividend Yield 2019 - 2021 (3 Years Smoothing)
Expectations and Forecasts
Future expectations provide potential trajectories for stock prices and aid investors in decision-making. The expected values are forecasted figures of fair value, taking into account the growth or decline trends of profit, revenue, or dividend.
Comparative Analysis
Comparing the fair value based on profit, revenue, and dividend provides a holistic overview of the stock’s financial health. Observing the annual and per-annual variations contributes to understanding the consistency and reliability of stock performance.
LigaChem Biosciences historical P/E ratio, EBIT, and P/S ratio.
LigaChem Biosciences shares outstanding KR7141080002 ·
The number of shares was LigaChem Biosciences in 2023 — This indicates how many shares 28.404 M is divided into. Since shareholders are the owners of a company, each share represents a small portion of the company's ownership.
3 years
5 years
10 years
25 Years
Max
Number of stocks
Details
Revenue, EBIT and Earnings per share
ⓘRevenue Per Share
Revenue per share represents the total revenue LigaChem Biosciences earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.
EBIT Per Share
EBIT per share indicates LigaChem Biosciences's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.
Income Per Share
Income per share, or earnings per share (EPS), reveals the portion of LigaChem Biosciences’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.
Expected Values
Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating LigaChem Biosciences's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.
| Number of stocks | |
|---|---|
| 2008 | 7 M Aktien |
| 2009 | 8 M Aktien |
| 2010 | 9 M Aktien |
| 2011 | 9 M Aktien |
| 2012 | 11 M Aktien |
| 2013 | 13 M Aktien |
| 2014 | 14 M Aktien |
| 2015 | 15 M Aktien |
| 2016 | 19 M Aktien |
| 2017 | 20 M Aktien |
| 2018 | 21 M Aktien |
| 2019 | 24 M Aktien |
| 2020 | 23 M Aktien |
| 2021 | 24.12 M Aktien |
| 2022 | 24.36 M Aktien |
| 2023 | 28.4 M Aktien |
| 2024e | 28.4 M Aktien |
| 2025e | 28.4 M Aktien |
| 2026e | 28.4 M Aktien |
LigaChem Biosciences Stock splits
In LigaChem Biosciences's history, there have been no stock splits.
Unfortunately, there are currently no price targets and forecasts available for LigaChem Biosciences.
LigaChem Biosciences latest earnings and earnings surprises
| Date | EPS Estimate | EPS Actual | Quarterly report |
|---|---|---|---|
| 6/30/2024 | 131.44 | -269 (-304.66 %) | 2024 Q2 |
1
LigaChem Biosciences list of shareholders
% | Name | Stocks | Change | Date |
|---|---|---|---|---|
| 6.66102 % | Kim (Yong Ju) | 2,426,428 | 0 | 9/30/2023 |
| 4.75932 % | National Pension Service | 1,733,693 | 325,301 | 9/30/2023 |
| 1.91904 % | The Vanguard Group, Inc. | 699,054 | 191,554 | 3/31/2024 |
| 1.41091 % | Templeton Asset Management Ltd. | 513,958 | -12,543 | 2/29/2024 |
| 1.19858 % | Franklin Templeton International Services SARL | 436,609 | -68,168 | 12/31/2023 |
| 1.11788 % | Samsung Asset Management Co., Ltd. | 407,214 | 2,179 | 2/29/2024 |
| 1.04737 % | Park (Se Jin) | 381,528 | 0 | 9/30/2023 |
| 0.82872 % | BlackRock Institutional Trust Company, N.A. | 301,882 | 638 | 3/31/2024 |
| 0.55159 % | UBS Hana Asset Management Company Ltd. | 200,929 | 28,752 | 9/30/2023 |
| 0.52905 % | Norges Bank Investment Management (NBIM) | 192,717 | 36,989 | 12/31/2023 |
1
2
3
4
5
...
7
Most common questions regarding LigaChem Biosciences
What is the P/S ratio of LigaChem Biosciences 2024?
The LigaChem Biosciences P/S ratio is 24.05.
What is the AlleAktien quality score of LigaChem Biosciences?
The AlleAktien quality score for LigaChem Biosciences is 5/10.
What is the revenue of LigaChem Biosciences 2024?
The expected LigaChem Biosciences revenue is 105.36 B KRW.
How high is the profit of LigaChem Biosciences 2024?
The expected LigaChem Biosciences profit is -22.79 B KRW.
What is the business model of LigaChem Biosciences
No history available for LigaChem Biosciences.
What is the LigaChem Biosciences dividend?
LigaChem Biosciences pays a dividend of 0 KRW distributed over payouts per year.
How often does LigaChem Biosciences pay dividends?
The dividend cannot currently be calculated for LigaChem Biosciences or the company does not pay out a dividend.
What is the LigaChem Biosciences ISIN?
The ISIN of LigaChem Biosciences is KR7141080002.
What is the LigaChem Biosciences ticker?
The ticker of LigaChem Biosciences is 141080.KQ.
How much dividend does LigaChem Biosciences pay?
Over the past 12 months, LigaChem Biosciences paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, LigaChem Biosciences is expected to pay a dividend of 0 KRW.
What is the dividend yield of LigaChem Biosciences?
The current dividend yield of LigaChem Biosciences is .
When does LigaChem Biosciences pay dividends?
LigaChem Biosciences pays a quarterly dividend. This is distributed in the months of .
How secure is the dividend of LigaChem Biosciences?
LigaChem Biosciences paid dividends every year for the past 0 years.
What is the dividend of LigaChem Biosciences?
For the upcoming 12 months, dividends amounting to 0 KRW are expected. This corresponds to a dividend yield of 0 %.
In which sector is LigaChem Biosciences located?
LigaChem Biosciences is assigned to the 'Health' sector.
Wann musste ich die Aktien von LigaChem Biosciences kaufen, um die vorherige Dividende zu erhalten?
To receive the latest dividend of LigaChem Biosciences from 9/15/2024 amounting to 0 KRW, you needed to have the stock in your portfolio before the ex-date on 9/15/2024.
When did LigaChem Biosciences pay the last dividend?
The last dividend was paid out on 9/15/2024.
What was the dividend of LigaChem Biosciences in the year 2023?
In the year 2023, LigaChem Biosciences distributed 0 KRW as dividends.
In which currency does LigaChem Biosciences pay out the dividend?
The dividends of LigaChem Biosciences are distributed in KRW.
LigaChem Biosciences stock price, news, forecast, analysis
Sector
Health
Industry
Life Sciences Tools & Services
Number of shares
Employee
Revenue growth Ø5 years
EBIT growth Ø5 years
Net Income growth Ø5 years
Website LigaChem Biosciences
Country
South Korea 🇰🇷
Currency
KRW
Initial public offering
May 10, 2013
GOSIN
Global Open Securities Identification Number
Cusip
Y5S30B101
Market capitalization
PEG
0
P/E
Forward P/E
-142.59
P/S
Forward P/S
10.87
ROE (Return on Equity)
ROA (Return on Assets)
ROCE (Return on Capital Employed)
ROIC
Scalable Capital savings plan Nein
Trade Republic savings plan Nein
comdirect savings plan
Consorsbank savings plan Nein
ING savings plan Nein
LigaChem Biosciences Peer Group
LigaChem Biosciences Eulerpool News
LigaChem Biosciences News
LigaChem Biosciences FIGI
| LigaChem Biosciences Ticker | LigaChem Biosciences FIGI |
|---|---|
| 141080:KS | BBG004D9DSR2 |
| 141080:KQ | BBG004D9DST0 |
All fundamentals about LigaChem Biosciences
Our stock analysis for LigaChem Biosciences Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of LigaChem Biosciences Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.
- LigaChem Biosciences Revenue
- LigaChem Biosciences Net Income
- LigaChem Biosciences P/E
- LigaChem Biosciences P/S
- LigaChem Biosciences EBIT
- LigaChem Biosciences Dividend
- LigaChem Biosciences Stocks
- LigaChem Biosciences Market capitalization
- LigaChem Biosciences Debt
- LigaChem Biosciences Liabilities
- LigaChem Biosciences Equity
- LigaChem Biosciences AAQS
- LigaChem Biosciences Employees
- LigaChem Biosciences ROE
- LigaChem Biosciences ROA
- LigaChem Biosciences ROCE